Goldman Sachs’s Oncolytics Biotech ONCY Stock Holding History

Goldman Sachs’s Portfolio ONCY Stock Details ONCY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$161K	Buy	+169,898	New	+$158K	﹤0.01%	6252
2026 Q1	–	Sell	-169,899	Closed	-$148K	–	6851
2025 Q4	$148K	Sell	169,899 -38,799	-19%	-$41.9K	﹤0.01%	6116
2025 Q3	$292K	Buy	208,698 +78,500	+60%	+$87.9K	﹤0.01%	5763
2025 Q2	$101K	Buy	130,198 +21,100	+19%	+$11.2K	﹤0.01%	5816
2025 Q1	$60K	Buy	109,098 +7,700	+8%	+$5.63K	﹤0.01%	5866
2024 Q4	$92.7K	Buy	101,398 +16,400	+19%	+$17.1K	﹤0.01%	5777
2024 Q3	$74K	Buy	84,998 +1,400	+2%	+$1.38K	﹤0.01%	5602
2024 Q2	$82.8K	Hold	83,598	–	–	﹤0.01%	5420
2024 Q1	$88.6K	Buy	+83,598	New	+$93.4K	﹤0.01%	5263
2021 Q2	–	Sell	-10,300	Closed	-$39K	–	6416
2021 Q1	$39K	Buy	+10,300	New	+$30.7K	﹤0.01%	5967

Other funds holding ONCY

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Seeds Investor New York $973M AUM 33.7% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

CCM

Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return

TAM

Tocqueville Asset Management New York $7.56B AUM 44.87% 1-Year Est. Return

EFG

Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

PFG Investments Woodbury, New York $2.58B AUM 36.93% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Goldman Sachs's ONCY Position: Q2 2026 in Review

Goldman Sachs opened a new position in Oncolytics Biotech (ONCY) in Q2 2026: 169,898 shares worth $161K. The stake represents ﹤0.01% of the portfolio and ranks #6252 among its holdings. This is a return to the name: Goldman Sachs previously reported a position in ONCY as recently as Q4 2025.

Goldman Sachs first reported a position in ONCY in Q1 2021 and has held it in 10 quarters since. The position peaked at $292K in Q3 2025. 75 funds tracked by Wall St. Rank hold ONCY as of Q2 2026.

Goldman Sachs held 169,898 shares of Oncolytics Biotech worth $161K as of Q2 2026.
Oncolytics Biotech was a new Goldman Sachs position in Q2 2026.
Oncolytics Biotech made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #6252 holding.
Goldman Sachs first reported a position in Oncolytics Biotech in Q1 2021 and has held it in 10 quarters since.
Goldman Sachs's Oncolytics Biotech position peaked at $292K in Q3 2025.
75 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.